BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines.
Mutations in the bone morphogenetic protein (BMP) type II receptor (BMPR-II) underlie most cases of heritable pulmonary arterial hypertension (HPAH) and a significant proportion of sporadic cases. Pulmonary artery smooth muscle cells (PASMCs) from patients with pulmonary arterial hypertension (PAH) not only exhibit attenuated growth suppression by BMPs, but an abnormal mitogenic response to transforming growth factor (TGF)-β1. We sought to define the mechanism underlying this loss of the antiproliferative effects of TGF-β1 in BMPR-II-deficient PASMCs. The effect of TGF-β1 on PASMC proliferation was characterized in three different models of BMPR-II dysfunction: 1) HPAH PASMCs, 2) Bmpr2(+/-) mouse PASMCs, and 3) control human PASMCs transfected with BMPR-II small interfering RNA. BMPR-II reduction consistently conferred insensitivity to growth inhibition by TGF-β1. This was not associated with altered canonical TGF-β1/Smad signaling but was associated with a secreted factor. Microarray analysis revealed that the transcriptional responses to TGF-β1 differed between control and HPAH PASMCs, particularly regarding genes associated with interleukins and inflammation. HPAH PASMCs exhibited enhanced IL-6 and IL-8 induction by TGF-β1, an effect reversed by NF-κB inhibition. Moreover, neutralizing antibodies to IL-6 or IL-8 restored the antiproliferative effect of TGF-β1 in HPAH PASMCs. This study establishes that BMPR-II deficiency leads to failed growth suppression by TGF-β1 in PASMCs. This effect is Smad-independent but is associated with inappropriately altered NF-κB signaling and enhanced induction of IL-6 and IL-8 expression. Our study provides a rationale to test anti-interleukin therapies as an intervention to neutralize this inappropriate response and restore the antiproliferative response to TGF-β1.
Division of Respiratory Medicine, Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK.
Rachel J
RJ
Davies
Alan M
AM
Holmes
John
J
Deighton
Lu
L
Long
Xudong
X
Yang
Lucy
L
Barker
Christoph
C
Walker
David C
DC
Budd
Paul D
PD
Upton
Nicholas W
NW
Morrell
D000818:Animals; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000172:deficiency* / Q000378:metabolism; D048708:Cell Growth Processes / Q000502:physiology; D002478:Cells, Cultured; D065627:Familial Primary Pulmonary Hypertension; D015870:Gene Expression; D006801:Humans; D006976:Hypertension, Pulmonary / Q000235:genetics / Q000378:metabolism; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism*; D016209:Interleukin-8 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D032389:Myocytes, Smooth Muscle / Q000378:metabolism*; D016328:NF-kappa B / Q000378:metabolism; D011651:Pulmonary Artery / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics; D051785:Smad Proteins / Q000378:metabolism; D014162:Transfection / Q000379:methods; D053773:Transforming Growth Factor beta1 / Q000378:metabolism*; D000093242:Interleukin-6 Inhibitors
D052006:Bone Morphogenetic Protein Receptors, Type II; D015850:Interleukin-6; D016209:Interleukin-8; D016328:NF-kappa B; D034741:RNA, Small Interfering; D051785:Smad Proteins; D053773:Transforming Growth Factor beta1; D000093242:Interleukin-6 Inhibitors